

# Denise Harold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/93393/publications.pdf>

Version: 2024-02-01

77  
papers

18,854  
citations

76294

40  
h-index

62565

80  
g-index

88  
all docs

88  
docs citations

88  
times ranked

21951  
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	9.4	3,741
2	Genome-wide association study identifies variants at <i>CLU</i> and <i>PICALM</i> associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1088-1093.	9.4	2,697
3	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates $A\beta$ , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
4	Common variants at <i>ABCA7</i> , <i>MS4A6A/MS4A4E</i> , <i>EPHA1</i> , <i>CD33</i> and <i>CD2AP</i> are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	9.4	1,708
5	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	6.0	1,085
6	Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1832.	3.8	1,064
7	Rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
8	Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. <i>Cell</i> , 2015, 162, 516-526.	13.5	514
9	Common polygenic variation enhances risk prediction for Alzheimer's disease. <i>Brain</i> , 2015, 138, 3673-3684.	3.7	359
10	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e13950.	1.1	347
11	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease. <i>Neuron</i> , 2013, 78, 256-268.	3.8	344
12	Increased expression of <i>BIN1</i> mediates Alzheimer genetic risk by modulating tau pathology. <i>Molecular Psychiatry</i> , 2013, 18, 1225-1234.	4.1	321
13	Strong Evidence That <i>KIAA0319</i> on Chromosome 6p Is a Susceptibility Gene for Developmental Dyslexia. <i>American Journal of Human Genetics</i> , 2005, 76, 581-591.	2.6	260
14	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , 2016, 21, 108-117.	4.1	260
15	Remapping the Insulin Gene/ <i>IGF2</i> Locus in Type 1 Diabetes. <i>Diabetes</i> , 2004, 53, 1884-1889.	0.3	198
16	Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. <i>Human Molecular Genetics</i> , 2013, 22, 832-841.	1.4	186
17	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.4	173
18	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	1.1	155

#	ARTICLE	IF	CITATIONS
19	Meta-analysis of the Association Between Variants in SORL1 and Alzheimer Disease. <i>Archives of Neurology</i> , 2011, 68, 99.	4.9	153
20	Further evidence that the KIAA0319 gene confers susceptibility to developmental dyslexia. <i>Molecular Psychiatry</i> , 2006, 11, 1085-1091.	4.1	140
21	Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. <i>Molecular Psychiatry</i> , 2015, 20, 1588-1595.	4.1	133
22	Characterization of a Family with Rare Deletions in CNTNAP5 and DOCK4 Suggests Novel Risk Loci for Autism and Dyslexia. <i>Biological Psychiatry</i> , 2010, 68, 320-328.	0.7	131
23	SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease. <i>PLoS Genetics</i> , 2010, 6, e1001101.	1.5	111
24	Genome-wide association study of Alzheimer's disease with psychotic symptoms. <i>Molecular Psychiatry</i> , 2012, 17, 1316-1327.	4.1	110
25	Missense variant in TREML2 protects against Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1510.e19-1510.e26.	1.5	110
26	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. <i>Molecular Psychiatry</i> , 2013, 18, 461-470.	4.1	103
27	Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene. <i>Translational Psychiatry</i> , 2014, 4, e358-e358.	2.4	98
28	Determining SNP Allele Frequencies in DNA Pools. <i>BioTechniques</i> , 2000, 28, 464-470.	0.8	91
29	A modifier of Huntington's disease onset at the MLH1 locus. <i>Human Molecular Genetics</i> , 2017, 26, 3859-3867.	1.4	88
30	A review of pharmaceutical occurrence and pathways in the aquatic environment in the context of a changing climate and the COVID-19 pandemic. <i>Analytical Methods</i> , 2021, 13, 575-594.	1.3	82
31	Alzheimer's disease genetics: current knowledge and future challenges. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 793-802.	1.3	79
32	Genetic evidence for the involvement of lipid metabolism in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 754-761.	1.2	66
33	Genome-wide association interaction analysis for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2436-2443.	1.5	61
34	Shared genetic contribution to ischemic stroke and Alzheimer's disease. <i>Annals of Neurology</i> , 2016, 79, 739-747.	2.8	56
35	The Role of Variation at APOE, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 377-387.	1.2	53
36	No consistent evidence for association between mtDNA variants and Alzheimer disease. <i>Neurology</i> , 2012, 78, 1038-1042.	1.5	52

#	ARTICLE	IF	CITATIONS
37	Analysis of Genome-Wide Association Studies of Alzheimer Disease and of Parkinson Disease to Determine If These 2 Diseases Share a Common Genetic Risk. <i>JAMA Neurology</i> , 2013, 70, 1268-76.	4.5	51
38	No support for association between Dyslexia Susceptibility 1 Candidate 1 and developmental dyslexia. <i>Molecular Psychiatry</i> , 2005, 10, 237-238.	4.1	49
39	Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 955-959.	1.1	47
40	Cognitive analysis of schizophrenia risk genes that function as epigenetic regulators of gene expression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 1170-1179.	1.1	43
41	Î±-T-Catenin Is Expressed in Human Brain and Interacts With the Wnt Signaling Pathway But Is Not Responsible for Linkage to Chromosome 10 in Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2004, 5, 133-146.	1.8	41
42	Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome. <i>Neurobiology of Aging</i> , 2014, 35, 1513.e1-1513.e5.	1.5	41
43	Association analysis of 528 intra-genic SNPs in a region of chromosome 10 linked to late onset Alzheimer's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 727-731.	1.1	40
44	A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 75-77.	0.7	36
45	Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. <i>Neurobiology of Aging</i> , 2013, 34, 2441.e1-2441.e5.	1.5	35
46	Genetic variation at the <i>CELFI1</i> (CUGBP, elav-like family member 1 gene) locus is genome-wide associated with Alzheimer's disease and obesity. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2014, 165, 283-293.	1.1	35
47	MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls. <i>Translational Psychiatry</i> , 2017, 7, e1012-e1012.	2.4	34
48	Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. <i>Human Genetics</i> , 2003, 113, 258-267.	1.8	33
49	A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer's disease risk. <i>Human Molecular Genetics</i> , 2013, 22, 816-824.	1.4	33
50	The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2015, 4, 279-284.	0.9	30
51	Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?. <i>Journal of Nuclear Medicine</i> , 2015, 56, 707-713.	2.8	30
52	Genetically predicted complement component 4A expression: effects on memory function and middle temporal lobe activation. <i>Psychological Medicine</i> , 2018, 48, 1608-1615.	2.7	29
53	Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C's Role in Working Memory. <i>Neuropsychopharmacology</i> , 2017, 42, 2612-2622.	2.8	28
54	Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 448-452.	1.1	27

#	ARTICLE	IF	CITATIONS
55	Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. <i>Neurobiology of Aging</i> , 2012, 33, 1843.e9-1843.e17.	1.5	24
56	Haplotype-based stratification of Huntington's disease. <i>European Journal of Human Genetics</i> , 2017, 25, 1202-1209.	1.4	24
57	Deep Sequencing of the Nicastrin Gene in Pooled DNA, the Identification of Genetic Variants That Affect Risk of Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e17298.	1.1	21
58	Rare Copy Number Variants Are Associated With Poorer Cognition in Schizophrenia. <i>Biological Psychiatry</i> , 2021, 90, 28-34.	0.7	20
59	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 764-771.	1.1	17
60	Monitoring of emerging contaminants of concern in the aquatic environment: a review of studies showing the application of effect-based measures. <i>Analytical Methods</i> , 2021, 13, 5120-5143.	1.3	17
61	Linkage disequilibrium structure of KIAA0319 and DCDC2, two candidate susceptibility genes for developmental dyslexia. <i>Molecular Psychiatry</i> , 2006, 11, 1061-1061.	4.1	13
62	Beyond C4: Analysis of the complement gene pathway shows enrichment for IQ in patients with psychotic disorders and healthy controls. <i>Genes, Brain and Behavior</i> , 2019, 18, e12602.	1.1	13
63	Identifying schizophrenia patients who carry pathogenic genetic copy number variants using standard clinical assessment: retrospective cohort study. <i>British Journal of Psychiatry</i> , 2020, 216, 275-279.	1.7	12
64	Effects of MiR-137 genetic risk score on brain volume and cortical measures in patients with schizophrenia and controls. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 369-376.	1.1	10
65	Characterisation and Validation of Insertions and Deletions in 173 Patient Exomes. <i>PLoS ONE</i> , 2012, 7, e51292.	1.1	8
66	The Differential Influence of Immune, Endocytotic, and Lipid Metabolism Genes on Amyloid Deposition and Neurodegeneration in Subjects at Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 127-139.	1.2	8
67	Effects of complement gene-set polygenic risk score on brain volume and cortical measures in patients with psychotic disorders and healthy controls. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020, 183, 445-453.	1.1	6
68	From Molecule to Clinic and Community for Neurodegeneration: Research to Bridge Translational Gaps. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S385-S396.	1.2	5
69	Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 595-598.	1.2	2
70	Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 223-231.	1.1	2
71	A03 Genetic Modifiers Affecting The Age At Motor Onset In Huntington's Disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A1-A2.	0.9	1
72	Biomarkers for Psychosis: the Molecular Genetics of Psychosis. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 112-118.	0.6	1

#	ARTICLE	IF	CITATIONS
73	RNA-seq analysis of murine peyer's patches at 6 and 18 h post infection with <i>Fasciola hepatica</i> metaceariae. <i>Veterinary Parasitology</i> , 2022, 302, 109643.	0.7	1
74	A COGNITIVE AND MOLECULAR ANALYSIS OF SDCCAG8, A SCHIZOPHRENIA RISK GENE THAT FUNCTIONS IN THE CENTROSOME. <i>European Neuropsychopharmacology</i> , 2019, 29, S876-S877.	0.3	0
75	O51. Beyond C4: Analysis of the Complement Gene Pathway Shows Enrichment for IQ in Patients With Schizophrenia and Healthy Controls. <i>Biological Psychiatry</i> , 2019, 85, S126-S127.	0.7	0
76	Genetic Risk Variants Interacting With MIR137: Effects On Cognition, Brain Structure And Brain Function In Patients And Healthy Participants. <i>European Neuropsychopharmacology</i> , 2019, 29, S729-S730.	0.3	0
77	43RARE COPY NUMBER VARIATIONS ARE ASSOCIATED WITH POORER COGNITION IN SCHIZOPHRENIA. <i>European Neuropsychopharmacology</i> , 2019, 29, S1091-S1092.	0.3	0